

# Resource Summary Report

Generated by NIF on Apr 19, 2025

## IQVIA

RRID:SCR\_021377

Type: Tool

---

### Proper Citation

IQVIA (RRID:SCR\_021377)

---

### Resource Information

**URL:** <https://www.iqvia.com/>

**Proper Citation:** IQVIA (RRID:SCR\_021377)

**Description:** IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research.

**Resource Type:** commercial organization

**Keywords:** American company, health information technology, clinical research

**Funding:**

**Resource Name:** IQVIA

**Resource ID:** SCR\_021377

**Record Creation Time:** 20220129T080355+0000

**Record Last Update:** 20250410T071337+0000

---

### Ratings and Alerts

No rating or validation information has been found for IQVIA.

No alerts have been found for IQVIA.

---

### Data and Source Information

Source: [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 26 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#).

Park SY, et al. (2025) A Systematic Literature Review to Determine Gaps in Diagnosing Suspected Infection in Solid Organ Transplant Recipients. *Open forum infectious diseases*, 12(1), ofaf001.

Moser K, et al. (2024) German primary care data collection projects: a scoping review. *BMJ open*, 14(2), e074566.

Bakris G, et al. (2024) Real-World Impact of Blood Pressure Control in Patients With Apparent Treatment-Resistant or Difficult-to-Control Hypertension and Stages 3 and 4 Chronic Kidney Disease. *American journal of hypertension*, 37(6), 438.

Ribeiro LC, et al. (2024) Needle in a haystack: Harnessing AI in drug patent searches and prediction. *PLoS one*, 19(12), e0311238.

Rasschaert M, et al. (2024) Malnutrition prevalence in cancer patients in Belgium: The ONCOCARE study. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer*, 32(2), 135.

Dhaini L, et al. (2024) Recommendations on Rapid Diagnostic Point-of-care Molecular Tests for Respiratory Infections in the United Arab Emirates. *The open respiratory medicine journal*, 18, e18743064319029.

Begun A, et al. (2023) A double-Cox model for non-proportional hazards survival analysis with frailty. *Statistics in medicine*, 42(18), 3114.

Hedenmalm K, et al. (2023) A collaborative study of the impact of N-nitrosamines presence and ARB recall on ARB utilization - results from IQVIA™ Disease Analyzer Germany. *European journal of clinical pharmacology*, 79(6), 849.

Swerdel JN, et al. (2023) Comparing broad and narrow phenotype algorithms: differences in performance characteristics and immortal time incurred. *Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques*, 26, 12095.

Burmester GR, et al. (2023) Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis. *Rheumatology and therapy*, 10(5), 1255.

Antoniou T, et al. (2023) Impact of the COVID-19 pandemic on antidepressant and

antipsychotic use among children and adolescents: a population-based study. *Frontiers in pediatrics*, 11, 1282845.

Moayyeri A, et al. (2023) Estimating the economic burden of osteoporotic fractures in a multinational study: a real-world data perspective. *Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA*, 34(12), 2121.

Bakris G, et al. (2023) Association of uncontrolled blood pressure in apparent treatment-resistant hypertension with increased risk of major adverse cardiovascular events plus. *Journal of clinical hypertension (Greenwich, Conn.)*, 25(8), 737.

Tompsett D, et al. (2023) Target Trial Emulation and Bias Through Missing Eligibility Data: An Application to a Study of Palivizumab for the Prevention of Hospitalization Due to Infant Respiratory Illness. *American journal of epidemiology*, 192(4), 600.

Lam T, et al. (2022) Pharmaceutical opioid poisonings in Victoria, Australia: Rates and characteristics of a decade of emergency department presentations among nine pharmaceutical opioids. *Addiction (Abingdon, England)*, 117(3), 623.

Uthayakumar S, et al. (2022) The effects of COVID-19 on the dispensing rates of antidepressants and benzodiazepines in Canada. *Depression and anxiety*, 39(2), 156.

Burn E, et al. (2022) Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study. *The Lancet. Infectious diseases*, 22(8), 1142.

Burn E, et al. (2022) Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: Incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries. *Pharmacoepidemiology and drug safety*, 31(5), 495.

Gomes T, et al. (2022) International trends in prescription opioid sales among developed and developing economies, and the impact of the COVID-19 pandemic: A cross-sectional analysis of 66 countries. *Pharmacoepidemiology and drug safety*, 31(7), 779.

Winglee K, et al. (2022) Decrease in Tuberculosis Cases during COVID-19 Pandemic as Reflected by Outpatient Pharmacy Data, United States, 2020. *Emerging infectious diseases*, 28(4), 820.